Skip to content

Bioventus BVS Repayments of Long-Term Lines of Credit

Repayments of Long-Term Lines of Credit at other companies

Enovis logo
EnovisENOV
Alphatec Holdings logo
Alphatec HoldingsATEC

Other financials

Income statement

See full
Revenue$132.1M+6.6%
Gross profit$90.8M+9.3%
Operating income$8.4M+72.8%
Net income$3.1M+218%
EPS (diluted)$0.04+200%

Balance sheet

See full
Cash & equivalents$35.8M+57.2%
Total debt$288.4M-21.2%
Total equity$188.9M+27.5%
Total assets$650.5M-5.9%

Cash flow

See full
Operating cash flow$8.9M+146%
CapEx$574.0K-30.5%
Free cash flow$8.4M+141%

Valuation

See full
Market cap$659.19M+51.7%
Enterprise value$911.76M+17.2%
P/E23.1×
P/S1.1×+0.4×

Profitability

See full
Gross margin68.7%+1.2pp
Operating margin10%
Net margin4.9%+3.2pp
FCF margin17.5%+13.2pp

Returns & leverage

See full
Return on equity16.9%+10.9pp
Debt / equity1.5×-0.9×
Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermLinesOfCredit.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's repayments of long-term lines of credit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bioventus's repayments of long-term lines of credit?
Bioventus (BVS) reported repayments of long-term lines of credit of $0 in Q1 2026.
How has Bioventus's repayments of long-term lines of credit changed year-over-year?
Bioventus's repayments of long-term lines of credit decreased by 100.0% year-over-year, from $5M to $0.
What is the long-term trend for Bioventus's repayments of long-term lines of credit?
Over 3 years (2022 to 2025), Bioventus's repayments of long-term lines of credit has grown at a 21.6% compound annual growth rate (CAGR), from $25M to $45M.